{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:56:19Z","timestamp":1793159779595,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104873","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:15:16Z","timestamp":1784330116000},"page":"104873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer\u20142026 Update"],"prefix":"10.1016","volume":"89","author":[{"given":"Andreas","family":"Hartkopf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute-Susann","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Bauerfeind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Banys-Paluchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Bjelic-Radisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Fallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Gluz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Heil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Heinrich","family":"Kreipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherko","family":"K\u00fcmmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Patrick","family":"Lux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Maass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion Tina","family":"van Mackelenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mundhenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjoung-Won","family":"Park-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattea","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toralf","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Rhiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Rody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Solbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich-Franz","family":"Solomayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Stickeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Thill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Witzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"W\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wuerstlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ditsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1365-2414","authenticated-orcid":false,"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104873_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12957-014-0429-x","article-title":"Age at diagnosis in relation to survival following breast cancer: a cohort study","volume":"13","author":"Brandt","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104873_bib2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.breast.2026.104873_bib3","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2026.104873_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1245\/s10434-014-3481-4","article-title":"Society of surgical oncology-American society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer","volume":"21","author":"Moran","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"9938","key":"10.1016\/j.breast.2026.104873_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.breast.2026.104873_bib6","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1158\/1078-0432.CCR-17-2947","article-title":"Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor","volume":"24","author":"Loibl","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104873_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104873_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/jclinpath-2017-204979","article-title":"Breast cancer histologic grading using digital microscopy: concordance and outcome association","volume":"71","author":"Rakha","year":"2018","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.breast.2026.104873_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12885-022-09193-0","article-title":"Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis","volume":"22","author":"Zhong","year":"2022","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.breast.2026.104873_bib10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41416-018-0256-x","article-title":"Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish cancer registry data","volume":"119","author":"Gray","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104873_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-020-06013-6","article-title":"Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer","volume":"186","author":"Richman","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.breast.2026.104873_bib12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104873_bib13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: the St Gallen international consensus conference for the primary therapy of individuals with early breast cancer 2023","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104873_bib14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2026.104873_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-020-05746-8","article-title":"Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer","volume":"183","author":"Walter","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104873_bib16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1186\/s12885-016-2766-3","article-title":"Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study","volume":"16","author":"Hennigs","year":"2016","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.breast.2026.104873_bib17","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1158\/0008-5472.CAN-18-0502","article-title":"Pooled analysis of nine cohorts reveals breast cancer risk factors by tumor molecular subtype","volume":"78","author":"Gaudet","year":"2018","journal-title":"Cancer Res"},{"issue":"9793","key":"10.1016\/j.breast.2026.104873_bib18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"8259","key":"10.1016\/j.breast.2026.104873_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(81)91341-6","article-title":"Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy","volume":"2","author":"Campbell","year":"1981","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.breast.2026.104873_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10549-017-4480-5","article-title":"Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials","volume":"167","author":"van Mackelenbergh","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.breast.2026.104873_bib21","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.breast.2026.104873_bib22","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.breast.2026.104873_bib23","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.breast.2026.104873_bib24","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104873_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.breast.2026.104873_bib26","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104873_bib27","article-title":"Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study","volume":"58","author":"Toli","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"22","key":"10.1016\/j.breast.2026.104873_bib28","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.breast.2026.104873_bib29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.breast.2026.104873_bib30","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine therapy response and 21-Gene expression assay for therapy guidance in HR+\/HER2- early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104873_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000453569","article-title":"PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer","volume":"11","author":"Hartkopf","year":"2016","journal-title":"Breast Care"},{"issue":"3","key":"10.1016\/j.breast.2026.104873_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.breast.2026.104873_bib33","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2026.104873_bib34","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jnci\/djab108","article-title":"PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer","volume":"113","author":"Rugo","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.breast.2026.104873_bib35","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104873_bib36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdt494","article-title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","volume":"25","author":"Gnant","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104873_bib37","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdv215","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104873_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.breast.2026.104873_bib39","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104873_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-019-05226-8","article-title":"Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone","volume":"176","author":"Sestak","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.breast.2026.104873_bib41","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104873_bib42","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2026.44.16_suppl.500","article-title":"First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer","volume":"44","author":"Stein","year":"2026","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104873_bib43","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.breast.2026.104873_bib44","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.2017.77.2285","article-title":"BRCA1\/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the GeparQuinto study","volume":"36","author":"Fasching","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.breast.2026.104873_bib45","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-Mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104873_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01200","article-title":"Mutations in BRCA1\/2 and other panel genes in patients with metastatic breast cancer -Association with patient and disease characteristics and effect on prognosis","author":"Fasching","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104873_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104873_bib48","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104873_bib49","article-title":"TBCRC 048 (Olaparib expanded) expansion cohorts: phase II study of olaparib monotherapy for patients with metastatic breast cancer with germline mutations in PALB2 or somatic mutations in BRCA1 or BRCA2","author":"Tung","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104873_bib50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000508675","article-title":"Endocrine-resistant breast cancer: mechanisms and treatment","volume":"15","author":"Hartkopf","year":"2020","journal-title":"Breast Care"},{"issue":"4","key":"10.1016\/j.breast.2026.104873_bib51","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","article-title":"Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer","volume":"25","author":"Browne","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104873_bib52","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.2024.42.16_suppl.1041","article-title":"Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+\/HER2- metastatic breast cancer (mBC) in the US","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104873_bib53","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3759179","article-title":"A systematic review of the prevalence and diagnostic workup of PIK3CA mutations in HR+\/HER2- metastatic breast cancer","volume":"2020","author":"Anderson","year":"2020","journal-title":"Int J Breast Cancer"},{"issue":"17","key":"10.1016\/j.breast.2026.104873_bib54","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-Mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.breast.2026.104873_bib55","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104873_bib56","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.breast.2026.104873_bib57","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2026.104873_bib58","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14737159.2019.1631799","article-title":"ESR1 mutations: a new biomarker in breast cancer","volume":"19","author":"Carausu","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"7","key":"10.1016\/j.breast.2026.104873_bib59","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.breast.2026.104873_bib60","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-20-0224","article-title":"ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials","volume":"26","author":"Turner","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.breast.2026.104873_bib61","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104873_bib62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mdx483","article-title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","volume":"29","author":"Fribbens","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104873_bib63","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.breast.2026.104873_bib64","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl_2","key":"10.1016\/j.breast.2026.104873_bib65","first-page":"S1","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104873_bib66","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"1\u20132","key":"10.1016\/j.breast.2026.104873_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000520561","article-title":"Liquid biopsy in metastatic breast cancer: current role of circulating tumor cells and circulating tumor DNA","volume":"45","author":"Banys-Paluchowski","year":"2022","journal-title":"Oncol Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2026.104873_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104296","article-title":"Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay","volume":"10","author":"Janni","year":"2025","journal-title":"ESMO Open"},{"issue":"17_suppl","key":"10.1016\/j.breast.2026.104873_bib69","doi-asserted-by":"crossref","first-page":"LBA507","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA507","article-title":"Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)","volume":"42","author":"Loi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104873_bib70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jnci\/djaa087","article-title":"Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer","volume":"113","author":"O'Leary","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.breast.2026.104873_bib71","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(25)00097-X","article-title":"Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial","volume":"26","author":"Kuemmel","year":"2025","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104873_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331203","article-title":"The SURVIVE study (NCT05658172): bringing breast cancer aftercare to the 21stcentury: study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors","volume":"20","author":"Braun","year":"2025","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.breast.2026.104873_bib73","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104873_bib74","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andre","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104873_bib75","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-Mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:26:24Z","timestamp":1789611984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":75,"alternative-id":["S0960977626001839"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104873","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer\u20142026 Update","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104873"}}